APUS Bathi resik saben saham sajrone 12 wulan pungkasan apimedsus.com

Apimeds Pharmaceuticals (APUS) strictly adheres to biochemical waste disposal regulations during the development of neurological drugs. Rolling year earnings per share demonstrate the business's financial stability, where -36.44 is recorded as the baseline value. The company is investing in renewable energy for its offices while simultaneously optimizing specialized raw material supply chains through the diversification of contract laboratories.

APUS Bathi saben saham sajroning taun lumaku Apimeds Pharmaceuticals (10.05.2025 - 14.11.2026)

Apimeds Pharmaceuticals, Inc. - rincian analitis lan metrik utama (APUS)

- rega saham lan target rega konsensus:

Rega saham Apimeds|APUS - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar Apimeds Pharmaceuticals US|APUS - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Apimeds Pharmaceuticals|APUS - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku apimedsus.com|APUS - Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas Apimeds Pharmaceuticals|APUS - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Apimeds|APUS - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Apimeds Pharmaceuticals US|APUS - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Apimeds Pharmaceuticals|Rasio cepet apimedsus.com

- data bathi lan kelipatan valuasi:

APUS - Bathi resik|Bathi sing dikarepake Apimeds Pharmaceuticals|APUS - Kapitalisasi marang bathi resik|Pangali Forward P/E Apimeds|APUS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Apimeds Pharmaceuticals US|APUS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Apimeds Pharmaceuticals|APUS - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan apimedsus.com|APUS - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Apimeds Pharmaceuticals

- rincian pendapatan lan dodolan emiten:

APUS - Pendapatan reged perusahaan|Volume dodolan mangsa ngarep perusahaan Apimeds|APUS - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan Apimeds Pharmaceuticals US

Analisis dhasar perusahaan:apimedsus.com (APUS)

The development of unique bee venom-based drugs and clinical trials in the US and Asia form the operational foundation of Apimeds Pharmaceuticals (APUS). These results translate into net income distributed per common share on a rolling year basis. This metric measures the actual efficiency of capitalization, excluding the impact of the total issuance volume. It allows for the differentiation of sustainable margins from one-time accounting adjustments. Analyzing the trend of the rolling annual EPS helps identify the risk of asset overvaluation in a timely manner.

Analisis perusahaan pesaing